Cytomegalovirus (CMV) infections manifest across a spectrum of clinical presentations, ranging from asymptomatic to severe life-threatening conditions. Immunocompromised individuals, such as those undergoing chemotherapy or organ transplant recipients, are particularly susceptible to symptomatic CMV infections. Common clinical manifestations include fever, fatigue, and organ-specific symptoms such as pneumonia or gastrointestinal complications. CMV retinitis, a sight-threatening condition, is prevalent in individuals with advanced HIV/AIDS. The management of CMV infections involves antiviral medications like ganciclovir, foscarnet, and cidofovir, which can help inhibit viral replication. Prophylactic use of these drugs is often considered in high-risk populations to prevent the onset of CMV-related complications. Despite advances in treatment, challenges remain, including the potential for drug resistance and the need for continued research to develop more effective therapeutic strategies. Ongoing efforts focus on understanding the immune response to CMV and developing vaccines to prevent primary infections and reactivations in at-risk populations.
Title : The role of the humoral innate immune system in evasion of streptococcus pyogenes infections
Francis J. Castellino, University of Notre Dame, United States
Title : Global environmental changes and mosquito-borne diseases in coastal areas
Ranjan Ramasamy, IDFISH Technology, United States
Title : The impact of global antibiotic resistance on the healthcare system, public health, environment and society
Reza Nassiri, Michigan State University, United States
Title : Current topics of adult COVID-19, Influenza, and RS virus patients in Japan
Seki Masafumi, Saitama Medical University International Medical Center, Japan
Title : Novel nanotechnology and its potential applications
Stephen Hsu, Augusta University, United States
Title : 2000 years of pandemics: Past, present and future
Claudia Ferreira, Biophytis Sorbonne, France